证券代码：601990 证券简称：南京证券 公告编号：临 2025-023 号 南京证券股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.08元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/5 | － | 2025/8/6 | 2025/8/6 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经南京证券股份有限公司（以下简称"公司"） 2025 年 6 月 30 日的2024年年度股东大会审议通过。 二、分配方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本 ...

Core Viewpoint - The report discusses the issuance of subordinate corporate bonds by Great Wall Securities Co., Ltd. aimed at professional investors, detailing the management of these bonds by Nanjing Securities Co., Ltd. and the recent resignation of the company's president and financial officer, Li Xiang [1][2][3]. Group 1: Bond Issuance - Great Wall Securities is set to issue subordinate corporate bonds in 2024 and 2025, with specific bond codes provided for each issuance [1]. - The bonds include varieties such as 2024 Phase I and II, and 2025 Phase I, all aimed at professional investors [2]. Group 2: Management Changes - Li Xiang, the president and financial officer of Great Wall Securities, submitted his resignation on July 17, 2025, due to personal reasons, effective immediately upon delivery of the resignation letter [2]. - Following Li Xiang's resignation, the board appointed Vice President Zhou Zhongshan to temporarily assume the roles of president and financial officer until a new appointment is made [2]. Group 3: Trustee Management Responsibilities - Nanjing Securities, as the trustee for the bonds, is responsible for ensuring compliance with relevant regulations and monitoring the issuer's disclosures regarding significant matters affecting bondholders [3]. - The trustee will continue to oversee the situation and ensure that the issuer adheres to information disclosure requirements [3].

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency while ensuring the safety of the funds and the implementation of investment projects [3][5][7]. Fundraising Overview - The company was approved to publicly issue 25 million shares at a price of RMB 40.29 per share, raising a total of RMB 100,725.00 million, with a net amount of RMB 90,975.85 million after deducting issuance costs [1][2]. - The funds are stored in a special account, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [2]. Investment Project Details - The total investment for the projects funded by the raised capital is RMB 65,000.48 million, with RMB 57,377.94 million planned from the raised funds and RMB 7,622.54 million from self-owned funds [2]. Cash Management Plan - The company intends to use up to RMB 52,600.00 million of temporarily idle funds for cash management within a 12-month period, ensuring it does not affect the implementation of investment projects [3][4][6]. - The investment products will include low-risk, high-liquidity options such as structured deposits, large-denomination certificates of deposit, and time deposits [4][5]. Impact on Operations - The cash management strategy is designed to improve fund efficiency without impacting the normal operations of the company or its investment projects, ultimately benefiting shareholders [5][7]. - The company aims to use the returns from cash management to supplement any shortfalls in project investments [4][5]. Approval Process - The board of directors and the supervisory board have approved the cash management plan, confirming compliance with relevant regulations and ensuring no adverse effects on the company's operations or shareholder interests [6][7][8].

Group 1 - The announcement states that Ms. Xiao Ling has resigned from her position as a director and member of the board's specialized committee due to work arrangement adjustments [1][2] - Ms. Xiao's resignation will not result in the board having fewer members than legally required, and her resignation is effective immediately upon delivery to the board [2] - The company expresses gratitude for Ms. Xiao's contributions during her tenure [3] Group 2 - The board has approved the nomination of Mr. Pan Zhipeng as a candidate for the board of directors, pending approval at the shareholders' meeting [2] - Ms. Xiao confirmed that there are no disagreements with the company or the board, and there are no special matters that need to be brought to the attention of shareholders and creditors [2]

Macro Dynamics - France will officially recognize the State of Palestine, with President Macron planning to announce this decision during the UN General Assembly in September [1] - China supports the "two-state solution" as the only realistic way to resolve the Palestinian issue and aims to work with the international community to alleviate the humanitarian crisis in Gaza [1] Foreign Exchange Market - In June 2025, China's foreign exchange market had a total transaction volume of 25.55 trillion RMB (approximately 3.56 trillion USD), with a cumulative transaction volume of 150.87 trillion RMB (approximately 21.00 trillion USD) from January to June 2025 [2] Fiscal Expenditure - In the first half of 2025, China's general public budget expenditure reached 141.27 billion RMB, a year-on-year increase of 3.4%, with significant growth in social security and employment (9.2%), science and technology (9.1%), education (5.9%), and health (4.3%) [3] Transportation and Mobility - In the first half of 2025, cross-regional personnel flow in China reached 33.76 billion person-times, a year-on-year increase of 4.2%, with freight volume and port cargo throughput also showing growth [5] Financial Institutions - Nanjing Securities announced the resignation of director Xiao Ling due to work arrangement adjustments [7] - HSBC Life Insurance increased its registered capital from 2.314 billion RMB to 2.676 billion RMB [8] Market Data - On July 25, 2025, A-shares saw a collective decline, with the Shanghai Composite Index down 0.33% and the Shenzhen Component down 0.22%, while the total market turnover was approximately 1.79 trillion RMB [10] - The Hong Kong stock market also experienced declines, with the Hang Seng Index down 1.09% [11] Company Dynamics - Chery Automobile clarified its collaboration with India's JSW Group, stating that it only involves parts supply and does not include technology transfer [12] - China Duty Free Group reported a net profit of 2.6 billion RMB in the first half of 2025, a year-on-year decrease of 20.81% [14][15] - Guangzhou-Shenzhen Railway signed a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion RMB [16] - Yushu Technology launched its third humanoid robot, UnitreeR1, priced from 39,900 RMB [17] - Ceconomy AG confirmed ongoing discussions with JD.com regarding a potential acquisition, with a possible valuation of around 2.2 billion EUR [18] - Country Garden's offshore debt restructuring is progressing, with a compensation plan of 178 million USD supported by key banks, expected to be completed by the end of December [19][20]

Group 1 - The core viewpoint of the article highlights the significant changes and developments in the Sci-Tech Innovation Board (STAR Market) since its inception, emphasizing its role in optimizing the A-share market structure and supporting key technological advancements in China [1] - As of July 22, 2025, a total of 591 companies have been listed on the STAR Market, with a cumulative IPO fundraising amount of 927.156 billion yuan and a total market capitalization exceeding 7 trillion yuan [1] - The STAR Market has become an important platform for tackling key core technologies under a new type of national system [1] Group 2 - In the past six years, the leading underwriters for IPOs on the STAR Market include Guotai Junan and Haitong Securities, with a combined total of 213.777 billion yuan raised from 112 underwriting cases [2][5] - CITIC Securities follows with 167.069 billion yuan from 99 cases, while China International Capital Corporation (CICC) and CITIC Jianzhong Securities rank third and fourth, respectively, in terms of underwriting volume [5] - The overall low rate of serious issues among listed companies is noted, with only 7 out of 591 companies facing significant problems, resulting in a low incidence rate of 1.18% [5][6] Group 3 - Nanjing Securities has faced scrutiny due to its involvement with ST Nuotai, which was flagged for financial misconduct shortly after its IPO, raising concerns about the quality of its ongoing supervision [7][9] - The company earned 211 million yuan in underwriting fees from three IPO projects, with ST Nuotai being a significant contributor despite its subsequent financial issues [7][8] - The regulatory body has not penalized Nanjing Securities for its oversight failures, despite the serious nature of the financial discrepancies found in ST Nuotai's reports [9][12]

肖玲女士的离任不会导致公司董事会成员低于法定人数，其辞职报告自送达 公司董事会之日起生效。肖玲女士确认与公司及董事会没有不同意见，亦无其他 需特别说明或提请公司股东和债权人注意的事项，并已按相关要求做好交接工作。 根据有关法律法规及公司《章程》等规定，并结合公司股东南京新工投资集团有 限责任公司的推荐意见，公司第四届董事会第十一次会议审议通过了《关于提名 董事候选人的议案》，同意提名潘志鹏先生（简历详见与本公告同日披露的本次 董事会会议决议公告）为第四届董事会董事候选人，其任期自股东大会审议通过 之日起至本届董事会届满之日止。该议案尚需提交公司股东大会审议。 关于公司董事离任的公告 公司对肖玲女士任职期间为公司作出的贡献表示衷心感谢！ 证券代码：601990 证券简称：南京证券 公告编号：临 2025-021 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京证券股份有限公司 一、提前离任的基本情况 南京证券股份有限公司（以下简称"公司"）于近日收到肖玲女士的辞职报 告，肖玲女士因工作安排调整申请辞去公司董事及董事会专门 ...

证券代码：601990 证券简称：南京证券 公告编号：临 2025-022 号 南京证券股份有限公司（以下简称"公司"）第四届董事会第十一次会议于 2025 年 7 月 25 日在公司总部以现场结合通讯方式召开，会议通知和材料于 2025 年 7 月 23 日以邮件方式发出，全体董事一致同意豁免本次会议的通知期限。会 议应出席董事 14 名，实际出席董事 14 名（其中，李剑锋董事长、夏宏建董事现 场出席会议，其他董事以视频方式出席会议）。本次会议的召集、召开及表决程 序符合有关法律法规、规章、规范性文件以及公司《章程》等规定。会议由李剑 锋董事长主持。会议作出如下决议： 一、审议并通过《关于提名董事候选人的议案》。 公司股东南京新工投资集团有限责任公司（以下简称"新工集团"）原推荐 肖玲女士担任公司董事，因工作安排调整，肖玲女士辞去公司第四届董事会董事、 董事会合规与风险管理委员会委员职务。新工集团推荐潘志鹏先生担任公司第四 届董事会董事。董事会同意提名潘志鹏先生（简历详见附件）为公司第四届董事 会董事候选人，并提请股东大会选举其为公司第四届董事会董事。潘志鹏先生将 在公司股东大会选举通过之日起正式担任公司 ...

Core Viewpoint - The stock of NuoTai Bio (688076.SH) was officially changed to "ST NuoTai" following the announcement of a financial fraud case, leading to an 11% drop in stock price on the first trading day after the change [1][2]. Group 1: Financial Fraud Details - NuoTai Bio's financial fraud was revealed in the "Administrative Penalty Notice" issued by the China Securities Regulatory Commission (CSRC), indicating that the company had fabricated financial data in its 2021 annual report [2][3]. - The fraudulent activity involved a technology transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability and operational capacity to pay for or utilize the technology, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the reported profit [3][4]. - NuoTai Bio also included false financial data in its convertible bond issuance documents, continuing to use the fraudulent 2021 financial figures in its fundraising materials [3]. Group 2: Penalties and Consequences - The CSRC proposed penalties against NuoTai Bio, including a fine of 47.4 million yuan and warnings for the company and its executives, with total penalties amounting to 76.2 million yuan, setting a record for penalties on the STAR Market [4][5]. - The actual controllers of NuoTai Bio, Zhao Dezhong and Zhao Deyi, received fines of 13 million yuan and 5 million yuan respectively, while four senior executives were fined between 1.5 million and 3.3 million yuan [4][5]. Group 3: Role of Nanjing Securities - Nanjing Securities, the sponsor for NuoTai Bio's IPO and convertible bond issuance, is implicated in the fraud due to its confirmation of the accuracy of the financial disclosures in the listing and bond issuance documents [6]. - Nanjing Securities earned approximately 66.3854 million yuan in underwriting fees from the IPO and around 5.66 million yuan from the convertible bond project [6]. - The firm has faced multiple issues with its sponsored projects, including instances of financial fraud and information disclosure violations [7][8].

Core Viewpoint - The company NuoTai Bio (688076.SH) has been penalized by the China Securities Regulatory Commission (CSRC) for financial fraud and has officially been designated as ST (Special Treatment) due to its violations, which include fabricating financial data and misleading disclosures [1][3]. Group 1: Company Violations - NuoTai Bio was found to have falsely recognized 30 million yuan in revenue through fictitious technology transfers, inflating profits by 25.95 million yuan, which accounted for 20.6% of the disclosed amount [1]. - The company also fabricated significant content in its public offering documents, with the 2023 convertible bond prospectus continuing to use this false data, constituting a serious violation of issuance document integrity [1][3]. Group 2: Underwriter's Responsibility - Nanjing Securities (601990.SH), as the underwriter for NuoTai Bio, was deeply involved in its financing operations and failed to identify the discrepancies in the financial disclosures, despite confirming the accuracy of the information provided [3][6]. - The underwriter received a total of 66.3854 million yuan in underwriting fees for the IPO and an additional 5.66 million yuan for the convertible bond project, raising questions about its due diligence practices [3][6]. Group 3: Regulatory and Market Impact - Following the scandal, Nanjing Securities has faced scrutiny for its oversight quality, with over 40% of the 17 IPO and refinancing companies it has supervised in the past decade encountering issues such as financial fraud and disclosure violations [6]. - Despite achieving a record net profit of 1 billion yuan in 2024, Nanjing Securities reported an 11.6% decline in revenue in the first quarter of 2025, indicating potential weaknesses in its business performance [7]. Group 4: Future Outlook - NuoTai Bio's stock will be subject to additional risk warnings from the Shanghai Stock Exchange, but it does not currently face mandatory delisting due to major legal violations [8]. - Nanjing Securities' 5 billion yuan private placement plan has faced delays and scrutiny, with the validity of the plan extended to July 2026, leaving its future uncertain [8].